Related Experiment Video

Updated: May 31, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

The Role of Mechanical Circulatory Support in Acute Myocardial Infarction Complicated by Cardiogenic Shock-Part Two:

Haris Patail1, Tanya Sharma2, Swati Chand3

  • 1Department of Cardiology, Westchester Medical Center, New York Medical College, 100 Woods Road, Valhalla, NY 10595, USA. Electronic address: https://twitter.com/harispatail.

Interventional Cardiology Clinics
|May 28, 2026
PubMed

Insights

Randomized trials on mechanical circulatory support for acute myocardial infarction with cardiogenic shock (AMI-CS) yield inconsistent results. Future trials may clarify optimal device choice and timing for AMI-CS treatment.

Area of Science:

  • Cardiology
  • Critical Care Medicine
  • Interventional Cardiology

Background:

  • Percutaneous coronary intervention and cardiac critical care have advanced.
  • Randomized controlled trials (RCTs) on mechanical circulatory support (MCS) for acute myocardial infarction complicated by cardiogenic shock (AMI-CS) show inconsistent outcomes.
  • Existing studies face limitations including small sample sizes, patient selection heterogeneity, variable intervention timing, and inconsistent shock severity definitions.

Purpose of the Study:

  • To review the current evidence on mechanical circulatory support in acute myocardial infarction complicated by cardiogenic shock.
  • To identify limitations in existing randomized controlled trials.
  • To discuss future directions for research in AMI-CS treatment.

Main Methods:

  • Review of randomized controlled trials investigating mechanical circulatory support in AMI-CS.
  • Analysis of limitations in current study designs and methodologies.
  • Discussion of emerging technologies and therapeutic strategies.

Main Results:

  • Inconsistent results from RCTs investigating MCS in AMI-CS.
  • Significant heterogeneity in patient populations, intervention timing, and shock severity assessment across studies.
  • Limited current evidence to guide optimal device selection and timing for AMI-CS.

Conclusions:

  • Current evidence provides insufficient guidance for optimal device choice and timing in AMI-CS.
  • Future trials incorporating next-generation percutaneous devices and early hemodynamic-guided interventions are needed.
  • Further research is essential to establish effective and safe treatment strategies for patients with AMI-CS.

Keywords:
Cardiogenic shockMechanical circulatory supportMyocardial infarctionPercutaneous coronary intervention

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

The Intra-Aortic Balloon Pump06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...